期刊文献+

水蛭素在毕赤酵母中的分泌表达 被引量:1

Secretory expression of hirudins in Pichia pastoris
在线阅读 下载PDF
导出
摘要 目的:构建水蛭素毕赤酵母表达载体,获得重组蛋白在毕赤酵母中的分泌型表达.方法:通过PCR扩增获得水蛭素HV2,HV2-N47K基因,将序列正确的基因序列插入酵母表达载体pPIC9α分泌信号下游,再亚克隆入高拷贝载体pPIC9K,构建表达质粒pPIC9K-HV2,pPIC9K-HV2-N47K.重组质粒转化宿主菌GSM1168,G418抗性筛选高拷贝的稳定表达菌株,经甲醇诱导表达并对表达产物进行鉴定.结果:成功构建了水蛭素毕赤酵母表达载体,获得水蛭素在毕赤酵母中的分泌型表达,表达产物具有抗凝血酶活性.结论:水蛭素在毕赤酵母中获得分泌型表达,为研究新药奠定了基础. AIM: To construct hirudin expression vectors and obtain its secretory expression in Pichia pastoris ( P. pastoris ). METHODS: Hirudin HV2 and HV2-N47K genes were amplified by PCR and the correct genes were fused to pPIC9 ot factor signal and subcloned into pPIC9K secretory expression vector. The constructs were transformed into P. pastoris strain GSM1168, stable multicopy integrants were screened on medium containing increasing concentrations of G418. Then the screened-out clones were induced by methanol to express hirudin proteins. The supernatants of expression products were identified by SDS-PAGE and Western blot analysis, and its antithrombotie activity was determined too. RESYLTS: The expression vectors were successfully constructed, hirudins were expressed in supematants of P. pastoris, and the expression products possessed antithrombotie activity. CONCLUSION : Hirudins can be expressed secretorily in P. pastoris, which offers a basis for newdrug researches.
出处 《第四军医大学学报》 北大核心 2006年第8期673-676,共4页 Journal of the Fourth Military Medical University
基金 国家自然科学基金资助(30200359)
关键词 水蛭素 毕赤酵母 分泌表达 hirudin Pichia secretory expression
  • 相关文献

参考文献8

  • 1Markwardt F. Hirudin as alternative anticoagulant-a historical review[J]. Semin Thromb Hemost, 2002,28(5) :405 -414.
  • 2Sohn JH, Kang HA, Rao KJ, et al. Current status of the anticoagulant hirudin: its biotechnological production and clinical practice [J]. Appl Microbiol Biotechnol, 2001,57(5-6) :606 -613.
  • 3Yavin YY, Wolozinsky M, Cohen AT. New antithrombotics in the prevention of thromboembolic disease[J]. Eur J Intern Med, 2005, 16(4) :257 -266.
  • 4龙铟,刘家云,刘莉,王宗仁.水蛭素基因毕赤酵母表达载体的构建及高拷贝稳定整合菌株的筛选[J].第四军医大学学报,2004,25(13):1228-1231. 被引量:4
  • 5龙铟,刘家云,刘莉,王宗仁.噬菌体改组库的构建及高活性水蛭素变异体的筛选[J].细胞与分子免疫学杂志,2006,22(2):167-170. 被引量:1
  • 6Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris [ J ]. FEMS Microbiol Rev, 2000,24( 1 ) :45 -66.
  • 7Boettner M, Prinz B, Holz C, et al. High-throughput screening for expression of heterologous proteins in the yeast Pichia pastoris [ J ].J Biotechnol, 2002,99( 1 ) :51 -62.
  • 8Daly R, Hearn MT. Expression of heterologous proteins in Pichia pastoris: A useful experimental tool in protein engineering and production[J]. J Mol Recognit, 2005,18(2) :119 -138.

二级参考文献19

  • 1龙铟,刘家云,刘莉,王宗仁.水蛭素基因毕赤酵母表达载体的构建及高拷贝稳定整合菌株的筛选[J].第四军医大学学报,2004,25(13):1228-1231. 被引量:4
  • 2Ruef J, Katus HA. New antithrombotic drugs on the horizon[J]. Expert Opin Investig Drugs, 2003; 12(5):781-797.
  • 3Markwardt F. Hirudin as alternative anticoagulantA historical review[J]. Semin Thromb Hemost, 2002; 28(5):405-414.
  • 4Sohn JH, Kang HA, Rao KJ, et al. Current status of the anticoagulant hirudin: Its biotechnological production and clinical practice[J]. Appl Microbiol Biotechnol, 2001; 57(5-6):606-613.
  • 5Sinclair G, Choy FY. Synonymous codon usage bias and the expression of human glucocerebrosidase in the methylotrophic yeast, Pichia pastoris[J]. Protein Expr Purif, 2002; 26(1):96-105.
  • 6Outchkourov NS, Stiekema WJ, Jongsma MA. Optimization of the expression of equistatin in Pichia pastoris[J]. Protein Expr Purif, 2002; 24(1):18-24.
  • 7Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris[J]. FEMS Microbiol Rev, 2000; 24(1):45-66.
  • 8Hollenberg CP, Gellissen G. Production of recombinant protein by methyloprophic yeasts[J]. Curr Opin Biotechnol, 1997; 8(5): 554-560.
  • 9Sohn JH,Kang HA,Rao KJ,et al.Current status of the anticoagulant hirudin:its biotechnological production and clinical practice[J].Appl Microbiol Biotechnol,2001,57(5-6):606-613.
  • 10Yavin YY,Wolozinsky M,Cohen AT.New antithrombotics in the prevention of thromboembolic disease[J].Eur J Intern Med,2005,16(4):257-266.

共引文献3

同被引文献13

  • 1Pineo G F, Hull R D. I4irudin and hirudin analogues as new anticoagulant agents. Curr Opin Hematol, 1995, 2 (5) : 380- 385.
  • 2Ruef Johannes, Katus Hugo A. New antithrombotic drugs on the horizon. Expert Opinion on Investigational Drugs, 2003, 12 (5) : 781-797.
  • 3Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res, 1994, 74(1) : 1-23,.
  • 4Rewinkel J B, Adang A E. Strategies and progress towards the ideal orally active thrombin inhibitor. Current Pharmaceutical Design, 1999, 5(12): 1043-1075.
  • 5Wallace A, Dennis S, Iofsteenge J, et al. Contribution of the N- terminal region of hirudin to its interaction with thrombin. Biochemistry, 1989,28 (26) : 10079-10084.
  • 6Wirsching F, Opitz T, Dietrich R, et al. Display of functional thrombin inhibitor hirudin on the surface of phage M13. Gene, 1997, 204(1-2) :177-184.
  • 7Syed S, Schuyler P D, Kulczycky M, et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood,1997,89(9) :3243-3252.
  • 8McKenzie C R, Abendschein D R, Eisenberg P R. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol, 1996,16 (10) : 1285-1291.
  • 9Zhang Chuanling, Yu Aiping, Yuan Bin, et al. Construction and functional evaluation of hirudin derivatives with low bleeding risk. Thrombosis and Haemostasis, 2008, 99 ( 2 ) : 324 -330.
  • 10Poet P, Scacheri E, Benatti L, et al. Production of the HV 1 variant of hirudin by recombinant DNA methodology. Blood Coagul Fibrinolysis, 1991,2 ( 1 ) : 113 -120.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部